Neoleukin Therapeutics (NASDAQ:NLTX) Trading 16.1% Higher

Neoleukin Therapeutics (NASDAQ:NLTX)’s stock price traded up 16.1% during trading on Wednesday . The stock traded as high as $9.97 and last traded at $9.66, 617,309 shares traded hands during mid-day trading. An increase of 7% from the average session volume of 577,081 shares. The stock had previously closed at $8.32.

Several equities research analysts have recently commented on the stock. Piper Sandler assumed coverage on shares of Neoleukin Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $20.00 price target for the company. ValuEngine lowered shares of Neoleukin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 3rd.

The company has a current ratio of 26.35, a quick ratio of 26.35 and a debt-to-equity ratio of 0.01. The firm has a market cap of $497.41 million, a price-to-earnings ratio of -7.88 and a beta of -6.95. The firm’s fifty day moving average price is $9.09.

Neoleukin Therapeutics (NASDAQ:NLTX) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.40). On average, equities research analysts forecast that Neoleukin Therapeutics will post -0.98 earnings per share for the current year.

In other news, Director Bros. Advisors Lp Baker acquired 3,017,542 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were purchased at an average price of $8.40 per share, with a total value of $25,347,352.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan G. Drachman acquired 119,047 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was purchased at an average cost of $8.40 per share, for a total transaction of $999,994.80. The disclosure for this purchase can be found here. 4.00% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of NLTX. State Street Corp purchased a new position in shares of Neoleukin Therapeutics in the 3rd quarter worth approximately $35,000. Virtu Financial LLC purchased a new position in shares of Neoleukin Therapeutics in the 3rd quarter worth approximately $57,000. California Public Employees Retirement System purchased a new position in shares of Neoleukin Therapeutics in the 3rd quarter worth approximately $162,000. Alpine Global Management LLC purchased a new position in shares of Neoleukin Therapeutics in the 4th quarter worth approximately $170,000. Finally, Millennium Management LLC purchased a new position in shares of Neoleukin Therapeutics in the 3rd quarter worth approximately $1,166,000. 38.75% of the stock is currently owned by hedge funds and other institutional investors.

Neoleukin Therapeutics Company Profile (NASDAQ:NLTX)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Further Reading: What is a stock split?

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.